General Biologicals Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

T.C. Lin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Shareholders of General Biologicals (GTSM:4117) Must Be Delighted With Their 340% Total Return

Feb 05

CEO

T.C. Lin

no data

Permanencia

Mr. T.C. Lin serves as Chairman and Chief Executive Officer at General Biologicals Corporation.

General Biologicals Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

General Biologicals Corporation, Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Less than half of directors are independent

General Biologicals Corporation, Annual General Meeting, Jun 17, 2021

Recent updates

New major risk - Financial position

Full year 2023 earnings released: NT$3.32 loss per share (vs NT$0.89 loss in FY 2022)

General Biologicals Corporation, Annual General Meeting, Jun 27, 2024

New minor risk - Financial data availability

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: NT$0.74 (vs NT$1.18 in FY 2020)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First half 2021 earnings released: EPS NT$0.88 (vs NT$0.053 loss in 1H 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS NT$1.18 (vs NT$0.99 loss in FY 2019)

General Biologicals Corporation, Annual General Meeting, Jun 17, 2021

New 90-day low: NT$43.00

Shareholders of General Biologicals (GTSM:4117) Must Be Delighted With Their 340% Total Return

New 90-day low: NT$44.00

New 90-day low: NT$55.60

General Biologicals Corporation (GTSM:4117) completed the acquisition of additional 77% stake in Pacgen Life Science Corporation (TSXV:PBS).

New 90-day low: NT$70.50

New 90-day low - NT$99.00

First half earnings released

General Biologicals Corporation announced that it has received TWD 77.623729 million in funding from Hong Kong Chlitina International Limited

CEO

Permanencia